Ge HY, Zhao BS, Zhang SH, Wang LP. Clinical efficacy of Qinggan Jiuwei San, a Mongolian drug, in treatment of alcoholic liver fibrosis.
Shijie Huaren Xiaohua Zazhi 2016;
24:4370-4374. [DOI:
10.11569/wcjd.v24.i32.4370]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM
To evaluate the clinical efficacy of Qinggan Jiuwei San, a Mongolian drug, in the treatment of patients with alcoholic liver fibrosis.
METHODS
Sixty-seven male patients with alcoholic liver fibrosis treated at the Affiliated Hospital of Inner Mongolia University for the Nationalities from June 2013 to May 2016 were divided into either an experimental group (n = 34) or a control group (n = 33). The experimental group was given oral Qinggan Jiuwei San (3 g each time, once a day) for a total of 12 wk. The control group was given reduced glutathione tablets (0.4 g each time, 3 times/d) for the same duration. Both groups abstained alcohol and other drugs during the experimental period. There was no statistically significant difference in general data (P > 0.05) between the two groups.
RESULTS
Qinggan Jiuwei San was superior to reduced glutathione in improving the FibroTest (FT) value and reducing collagen Ⅳ(CⅣ) and laminin (LN) indexes. Both Qinggan Jiuwei San and reduced glutathione showed good efficacy in reducing serum liver fibrosis indexes hyaluronan (HA) and procollagen Ⅲ peptide (PⅢP). Qinggan Jiuwei San was significantly better than reduced glutathione in reducing HA, PCⅡ, CⅣ and LN.
CONCLUSION
Qinggan Jiuwei San can improve the FT value of patients with alcoholic liver fibrosis, and reduce the degree of hepatic fibrosis.
Collapse